<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04956328</url>
  </required_header>
  <id_info>
    <org_study_id>ABDS-CS-01</org_study_id>
    <nct_id>NCT04956328</nct_id>
  </id_info>
  <brief_title>Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC)</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind Trail Evaluating the Efficacy and Safety of Combination of Obecholic Acid and UDCA Compared With UDCA Monotherapy in PBC Patients With an Inadequate Response to UDCA .</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obecholic acid is a modified bile acid and Farnesoid X receptor (FXR) agonist. FXR is a key&#xD;
      regulator of bile acid synthesis and transport. Bile acids are used by the body to help with&#xD;
      digestion. Conventional therapy with obecholic acid will improve liver function of patients&#xD;
      with PBC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2021</start_date>
  <completion_date type="Anticipated">September 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of PBC patients reaching the compound endpoint after 48 weeks of treatment (Compound endpoint: alkaline phosphatase (ALP) &lt; 1.67× Upper Limit of Normal(ULN), ALP decrease by at least 15% , and total bilirubin ≤ ULN )</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Compound endpoint: ALP &lt; 1.67× ULN, ALP decrease by at least 15% , and total bilirubin ≤ ULN</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of PBC patients reaching the compound endpoint after 4 weeks, 12 weeks, 24 weeks and 36 weeks of treatment (Compound endpoint: ALP &lt; 1.67× ULN, ALP decrease by at least 15% , and total bilirubin ≤ ULN )</measure>
    <time_frame>up to 36 weeks</time_frame>
    <description>Compound endpoint: ALP &lt; 1.67× ULN, ALP decrease by at least 15% , and total bilirubin ≤ ULN</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change of liver function indicators from baseline</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>Liver function: ALP (alkaline phosphatase ), ALT (Alaninetransaminase), AST(aspartate transaminase), GGT( γ-glutamyl transpeptadase ), TBA (total bile acid) and Tbil (total bilirubin)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>OCA Tablets 5-10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 5 mg once daily in combination with UDCA for 24 weeks and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily in combination with UDCA for 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid Tablets</intervention_name>
    <description>Obeticholic Acid：Once a day (QD) by mouth (PO).</description>
    <arm_group_label>OCA Tablets 5-10 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UDCA</intervention_name>
    <description>UDCA：continue prestudy dose</description>
    <arm_group_label>OCA Tablets 5-10 mg</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 18 to 75 years.&#xD;
&#xD;
          2. Meet at least 2 of the following 3 PBC diagnoses:&#xD;
&#xD;
               1. Patients had elevated alkaline phosphatase for at least 3 months before&#xD;
                  enrolment.&#xD;
&#xD;
               2. AMA positive (titer ≥1:40), or if AMA negative, PBC specific antibodies (anti-&#xD;
                  GP210 and/or anti-SP100 and/or AMA-M2) are required.&#xD;
&#xD;
               3. Liver biopsy suggested PBC 48 weeks before enrollment.&#xD;
&#xD;
          3. ALP &gt; 1.67× ULN before enrollment.&#xD;
&#xD;
          4. Taking UDCA with stable dose for at least 3 months before enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Merging with other virus infected.&#xD;
&#xD;
          2. With other existing liver disease or a history of liver disease.&#xD;
&#xD;
          3. With clinical complications of PBC or clinically significant hepatic decompensation.&#xD;
&#xD;
          4. Child-pugh grade B or C.&#xD;
&#xD;
          5. Creatinine (Cr) ≥ 1.5×ULN and serum creatinine clearance rate &lt; 60mL/min; [Calculation&#xD;
             formula: Cr:(140-age)×weight(kg) /0.818 × Scr (μmol/L)，female Cr=Cr × 0.85].&#xD;
&#xD;
          6. ALT or AST&gt;5×ULN;Tbil &gt; 2×ULN.&#xD;
&#xD;
          7. Patients with a history of severe pruritus 2 months before enrollment.&#xD;
&#xD;
          8. The presence of clinically relevant arrhythmias or associated history that may affect&#xD;
             survival during the study period.&#xD;
&#xD;
          9. With diseases that may cause nonhepatic ALP increases (e.g., Paget's disease) or which&#xD;
             may diminish life expectancy to &lt; 2 years.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junqi Niu, Professor</last_name>
    <phone>13756661205</phone>
    <email>junqiniu@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The first hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junqi Niu</last_name>
      <phone>13756661205</phone>
      <email>junqiniu@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Junqi Niu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2021</study_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

